Skip to main content
Log in

A comparison of low versus high radioiodine administered activity in patients with low-risk differentiated thyroid cancer

  • Review Article
  • Published:
European Archives of Oto-Rhino-Laryngology Aims and scope Submit manuscript

Abstract

Post-surgical therapeutic management of differentiated thyroid cancer (DTC) is still a controversial subject. Indeed, there is no consensus on the dose of 131I to be administered, although the current trend towards therapy easing through mini-cures for patients with good prognosis. To confirm the non-inferiority in terms of effectiveness of an ablative mini-cure from 1.11 to 1.85 GBq, over a cure of 3.7 GBq, in patients with DTC operated for low and very low risk. We retrospectively studied 157 patients with very low and low risk DTC, followed in the Nuclear Medicine Department of the Salah Azaiez Institute between 2002 and 2012. These patients had a complementary radioiodine therapy with either low dose (group A) or high dose (group B) with an evaluation at 6 months post treatment and in long-term. The study took place at a referral center. The average age was 42.8 ± 13.7 years with a female predominance (86.7 %). The DTC papillary represented the most common etiology (95 %) with a predominance of pure papillary (68 %) on the follicular variant (27 %). The first cure evaluation did not show statistically significant difference between the two approaches in terms of therapeutic ablative efficiency (p = 0.13). The overall success rate was 77 % (121/157), with 83 % (54/65) in group A and 72.8 % (67/92) in group B. The likelihood of having a remission from the first cure was 1.83 times greater for patients treated with low doses (OR = 1.83, 95 % CI 0.23–1.29). At the end of follow, we have noted one case of refractory disease. The male gender (adjusted OR = 2.71, 95 % CI 0.51–4.23, p = 0.03), and the baseline Tg ≥ 10 (ng/ml) (adjusted OR = 3.48, 95 % CI 1.25–9.67, p = 0.01) were significantly independent predictors of successful first cure ablation. The results provide that mini-dose protocol is not less effective for ablation of the thyroid remnant than 3.7 GBq activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE et al (2016) 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133

    Article  PubMed  PubMed Central  Google Scholar 

  2. Siddiqui AR, Edmondson J, Wellman HN, Hamaker RC, Lingeman RE, Park HM et al (1981) Feasibility of low doses of I-131 for thyroid ablation in postsurgical patients with thyroid carcinoma. Clin Nucl Med 6(4):158–161

    Article  CAS  PubMed  Google Scholar 

  3. Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L et al (2002) Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 87(9):4063–4068

    Article  CAS  PubMed  Google Scholar 

  4. Creutzig H (1987) High or low dose radioiodine ablation of thyroid remnants? Eur J Nucl Med 12(10):500–502

    Article  CAS  PubMed  Google Scholar 

  5. Bal CS, Kumar A, Pant GS (2004) Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab 89(4):1666–1673

    Article  CAS  PubMed  Google Scholar 

  6. Maenpaa HO, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu H (2008) Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS One 3(4):e1885

    Article  PubMed  PubMed Central  Google Scholar 

  7. Ramanna L, Waxman AD, Brachman MB, Tanasescu DE, Sensel N, Braunstein GD (1985) Evaluation of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients. Clin Nucl Med 10(11):791–795

    Article  CAS  PubMed  Google Scholar 

  8. Johansen K, Woodhouse NJ, Odugbesan O (1991) Comparison of 1073 and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med 32(2):252–254

    CAS  PubMed  Google Scholar 

  9. Bal C, Padhy AK, Jana S, Pant GS, Basu AK (1996) Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 77(12):2574–2580

    Article  CAS  PubMed  Google Scholar 

  10. Muratet JP, Daver A, Minier JF, Larra F (1998) Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med 39(9):1546–1550

    CAS  PubMed  Google Scholar 

  11. Doi SA, Woodhouse NJ (2000) Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. Clin Endocrinol Oxf 52(6):765–773

    Article  CAS  PubMed  Google Scholar 

  12. Dietlein M, Moka D, Scheidhauer K, Schmidt M, Theissen P, Voth E et al (2000) Follow-up of differentiated thyroid cancer: comparison of multiple diagnostic tests. Nucl Med Commun 21(11):991–1000

    Article  CAS  PubMed  Google Scholar 

  13. Rosario PW, Barroso AL, Rezende LL, Padrao EL, Borges MA, Fagundes TA et al (2005) Ablative treatment of thyroid cancer with high doses of 131I without pre-therapy scanning. Nucl Med Commun 26(2):129–132

    Article  CAS  PubMed  Google Scholar 

  14. Leger FA, Izembart M, Dagousset F, Barritault L, Baillet G, Chevalier A et al (1998) Decreased uptake of therapeutic doses of iodine-131 after 185 MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 25(3):242–246

    Article  CAS  PubMed  Google Scholar 

  15. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M (2000) Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 85(1):175–178

    Article  CAS  PubMed  Google Scholar 

  16. de Klerk JM, de Keizer B, Zelissen PM, Lips CM, Koppeschaar HP (2000) Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy. Nucl Med Commun 21(6):529–532

    Article  PubMed  Google Scholar 

  17. Bernier MO, Morel O, Rodien P, Muratet JP, Giraud P, Rohmer V et al (2005) Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 32(12):1418–1421

    Article  CAS  PubMed  Google Scholar 

  18. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B et al (2012) Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med 366(18):1663–1673

    Article  CAS  PubMed  Google Scholar 

  19. Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L et al (2012) Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med 366(18):1674–1685

    Article  CAS  PubMed  Google Scholar 

  20. Doi SA, Woodhouse NJ, Thalib L, Onitilo A (2007) Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited. Clin Med Res 5(2):87–90

    Article  PubMed  PubMed Central  Google Scholar 

  21. Kukulska A, Krajewska J, Gawkowska-Suwinska M, Puch Z, Paliczka-Cieslik E, Roskosz J et al (2010) Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi. Thyroid Res 3(1):9

    Article  PubMed  PubMed Central  Google Scholar 

  22. Sirisalipoch S, Buachum V, Tepmongkol S, Boonvisut S (2006) Prospective randomised trial for the evaluation of the efficacy of low vs. high dose I-131 for post operative remnant ablation in differentiated thyroid cancer. Chula Med J 50(10):695–706

    Google Scholar 

  23. Kim EY, Kim TY, Kim WG, Yim JH, Han JM, Ryu JS et al (2011) Effects of different doses of radioactive iodine for remnant ablation on successful ablation and on long-term recurrences in patients with differentiated thyroid carcinoma. Nucl Med Commun 32(10):954–959

    Article  CAS  PubMed  Google Scholar 

  24. Fallahi B, Beiki D, Takavar A, Fard-Esfahani A, Gilani KA, Saghari M et al (2012) Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial. Nucl Med Commun 33(3):275–282

    Article  CAS  PubMed  Google Scholar 

  25. Welsh L, Powell C, Pratt B, Harrington K, Nutting C, Harmer C et al (2013) Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancer. J Clin Endocrinol Metab 98(5):1819–1825

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to I. Yeddes.

Ethics declarations

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ben Ghachem, T., Yeddes, I., Meddeb, I. et al. A comparison of low versus high radioiodine administered activity in patients with low-risk differentiated thyroid cancer. Eur Arch Otorhinolaryngol 274, 655–660 (2017). https://doi.org/10.1007/s00405-016-4111-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00405-016-4111-5

Keywords

Navigation